Hepatitis C Virus Infection Completed Phase 2 Trials for Daclatasvir (DB09102)

DBCOND0033268 (Hepatitis C Virus Infection)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04019717Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) InfectionTreatment
NCT01428063Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsTreatment